Skip to main content
. 2011 Jul 1;2(4):440–448. doi: 10.4161/mabs.2.4.12203

Figure 4.

Figure 4

5-Azacytidine significantly enhances lintuzumab (SGN-33)-mediated ADCP activity and increased the expression of CD32 on human macrophages. Macrophages isolated from human PBMCs cultured long-term in GM-CSF were pre-treated with 10 nM or 100 nM 5-azacytidine prior to addition of lintuzumab-treated AML cell lines, HL60cy (A) or HEL9217 (B). 5-azacytidine significantly enhanced lintuzumab-mediated ADCP activity (p < 0.018, 2-way ANOVA). Data shown are mean ± SEM of triplicate values from two to three separate experiments using macrophages from different donors. (C) Flow cytometry analyses of the Fcγ receptors CD32, CD16 and CD64 on human macrophages incubated with 100 nM 5-azacytidine or vehicle for 18 h. Data (gating on live cells) are expressed as ratio of MFI for each marker to MFI for the isotype control. Data from two separate experiments using cells from two different donors (MAC # 1 and MAC # 2) are shown and expressed as mean ± SD of duplicate values. *p < 0.05 to No 5-azacytidine.